illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. Daan Gene
Company logo

Daan Gene | Sustainability Performance

https://en.daangene.com/
Linkedin

Develops and supplies diagnostic reagents and medical testing equipment, specializing in genetic testing.

1993

China

1,001 - 5,000 employees

Biotechnology

$100M - 500M in revenue

N/A in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#11504
Overall
#689
in China
#234
in Biotechnology

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
BioKangtai

China, Hospital & Health Care, Biotechnology


Company logo
Shandong Buchang Pharmaceuticals

China, Hospital & Health Care, Pharmaceuticals


Company logo
INT Medical Instruments

China, Hospital & Health Care, Medical Device

Market cap

54.6B $, 2026▼19.5% YoY

Revenue

106.2M $, 2025▼12.7% YoY

R&D intensity

24.57% 2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

54.6B $, 2026▼19.5% YoY

Revenue

106.2M $, FY2025▼12.7% YoY

EBITDA

-41.7M $, FY2025▼9.1% YoY

Operating margin

-39% Industry: -370▼219.1% YoY

Revenue & EBITDA

$106.2MFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

17.7M 2024▼64.7% YoY

Capex

24.4M 2024▼228.7% YoY

R&D intensity

24.6%FY2025

R&D as % of revenue

R&D as % of revenue
Industry benchmark

Powered by illuminem

Return on invested capital

-10.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.2

2023

0.1

2024

0.1

▼ 68.4%

2025

0.8

2027

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Available

27%
Independent Directors

3 out of 11 incl. management

Powered by illuminem

Overall score

25

Environment

29

Social

32

Governance

15

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email